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Men Are From an ASTEROID
Deciphering the REVERSAL of Coronary Atheroma*Hector M. Garcia-Garcia, MD, MSC, PHD,y Carlos M. Campos, MD,yz Patrick W. Serruys, MD, PHDyW omen are under-represented (range from8% to 68%) in most lipid-lowering ran-domized clinical trials. Meta-analysis
data from 170,000 participants showed that women
had a signiﬁcant proportional risk reduction of 16%
(99% conﬁdence interval: 3% to 27%; p ¼ 0.002 per
1.0 mmol/l decrease in low-density lipoprotein
cholesterol [LDL-C]) of the combined endpoint of cor-
onary death, nonfatal myocardial infarction coronary
revascularization, and stroke (1). Is this because
women had a greater change in intravascular ultra-
sound (IVUS) percentage atheroma volume (PAV)
in progression/regression trials, as shown in this sub-
study of the SATURN (Study of Coronary Atheroma
by Intravascular Ultrasound: Effect of Rosuvastatin
Versus Atorvastatin) study (2)? This observation hasTABLE 1 Sex-Related Changes in Percentage Atheroma Volume
at 24 Months in Different Progression/Regression Trials
SEE PAGE 1013not been proven to be a consistent one. In the
ASTEROID (A Study To Evaluate the Effect of Rosu-
vastatin on Intravascular Ultrasound-Derived Coro-
nary Atheroma Burden) study, in which high dose
rosuvastatin was administered, the ﬁndings were at
variance with the current report (Table 1). Men had
slightly larger regression than women. Of note, the
IVUS analyses were performed under the same stan-
dard operating procedures in the same analysis core
laboratory in both studies. Why did the differential
impact of rosuvastatin and atorvastatin on plaque
regression in women was not reproduced?*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
From the yDepartment of Interventional Cardiology, Erasmus University
Medical Centre, Thoraxcenter, Rotterdam, the Netherlands; and the
zHeart Institute (InCor), University of São Paulo Medical School, São
Paulo, Brazil. All authors have reported that they have no relationships
relevant to the contents of this paper to disclose.In the SATURN trial subgroup analysis, overall
(taking both groups together: rosuvastatin- and
atorvastatin-treated patients) women had a greater
reduction in PAV (–1.52  0.18% vs. –1.07  0.10%, p ¼
0.03) (2), but only in cases with LDL-C levels <70 mg/
dl. Interestingly, the percentage of women that ach-
ieved LDL-C levels <70 mg/dl was smaller compared
to men (61.7% vs. 65.0%, respectively). Thus, women
showed more regression despite that they were fewer
achieving the target of LCL-C. Taken all together, it
is interesting to see that even in the best-case sce-
nario, namely in the context of a large randomized
clinical trial, less than two-thirds of patients achieved
the per protocol target (LDL-C levels <70 mg/dl).
Is percentage atheroma volume the best para-
meter to compare women versus men? The percent
atheroma volume with as numerator atheroma vol-
ume and as denominator vessel volume, may mask
the speciﬁc directional changes in its numerator and
denominator (3) when used as primary endpoint to
compare 2 pharmacological agents or 2 groups; it has,
though, a lower variation (smaller SD) than atheroma
volume and therefore has been used as a primary
endpoint in many IVUS studies. In Table 2, it can be
seen that, looking purely at the actual atheroma size
changes without normalizing for the vessel volume,
in all studies with the exception of the ASTEROIDSATURN SATURN ASTEROID
Rosuvastatin
40 mg
Atorvastatin
80 mg
Rosuvastatin
40 mg
Male –1.09 –1.03 –0.8
Female –1.76 –0.71 –0.7
ASTEROID ¼ A Study To Evaluate the Effect of Rosuvastatin on Intravascular
Ultrasound-Derived Coronary Atheroma Burden; SATURN ¼ Study of Coronary
Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
TABLE 2 Atheroma Volume Changes by Sex
SATURN SATURN ASTEROID REVERSAL
24 Months 24 Months 24 Months 18 Months
40 mg
Rosuvastatin*
80 mg
Atorvastatin*
40 mg
Rosuvastatin†
80 mg
Atorvastatin‡
Male –7.21 –5.62 –6.1 0.7
Female –9.68 –7.70 –4.2 –2.3
*Adjusted change from baseline in atheroma volume. †Atheroma volume in most diseased 10-mm subsegments.
‡Median percentage change in atheroma volume.
REVERSAL ¼ Reversing Atherosclerosis with Aggressive Lipid Lowering; other abbreviations as in Table 1.
Garcia-Garcia et al. J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 1 0 , 2 0 1 4
Editorial Comment O C T O B E R 2 0 1 4 : 1 0 2 3 – 4
1024trial, women showed more atheroma volume regres-
sion than men.
Additional lessons learned from previous progres-
sion/regression trials, in general:
1. The larger the PAV at baseline is, the larger the
regression in PAV is (4).
2. The larger the reduction in LDL-C is, the larger the
regression in PAV is (5).
3. The higher the increase in high-density lipoprotein
cholesterol (HDL-C) is, the larger the regression in
PAV is (5).
4. The larger the reduction in C-reactive protein (CRP)
levels is, the larger the regression in PAV is (6).
Yet, in this substudy from the SATURN trial,
women had a larger regression in PAV compared to
men, despite the fact that women had smaller plaques
at baseline and they had on average higher levels
of CRP. As mentioned previously, women, in lipid-
lowering trials, had a reduction of the combined
endpoint of coronary death, nonfatal myocardial
infarction coronary revascularization and stroke.
Moreover, in another substudy of the SATURN trial,
the CRP levels were associated with major adversecardiac events (MACE) (7), which makes it harder to
dissect this complex interplay between women and
CRP and their association with MACE.
Is it then the greater reduction in PAV in women
related to the fact that they had on treatment lower
LDL-C and higher HDL-C values? In this report
(SATURN trial gender analysis), compared with
men, women had higher HDL-C at baseline and
follow-up. In the REVERSAL (Reversing Athero-
sclerosis with Aggressive Lipid Lowering) trial (8),
the patients with HDL-C above the mean who were
treated with atorvastatin had a regression of –1.5%
(p ¼ 0.97 for the comparison with baseline), but not
their counterparts. At variance, in this SATURN trial
gender analysis, irrespective of the baseline HDL-C
(above or below the mean), there was a signiﬁcant
reduction in PAV. Thus, the association of ath-
eroma changes and HDL-C need to be further
elucidated.
Many of the lessons learned in previous progres-
sion/regression trials have been challenged in this
gender report of the SATURN study. In order to get
clarity on whether there is a differential impact of
gender on coronary atheroma size or these changes
in plaque size are due to other potential confounding
factors, we would like to encourage the authors
to pool the data of the SATURN, ASTEROID, and
REVERSAL studies to further elucidate these
observations.
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